153P Adjuvant endocrine therapy combined with abemaciclib in monarchE patients with high-risk early breast cancer: Disease characteristics and endocrine therapy choice by menopausal status-Reference-Cited by-同舟云学术

153P Adjuvant endocrine therapy combined with abemaciclib in monarchE patients with high-risk early breast cancer: Disease characteristics and endocrine therapy choice by menopausal status

Published:2021-09 Issue: Volume:32 Page:S427-S428
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Paluch-Shimon S.,Lueck H.,Beith J.,Tokunaga E.,Contreras J. Reyes,de Sant’Ana R.O.,Forrester T.,McNaughton R.,Wei J.,Harbeck N.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Endokrine Therapielandschaft bei Patient*innen mit HR+ HER2− frühem Mammakarzinom in Deutschland vor Einführung der CDK4/6-Inhibitor-Behandlung – eine Real-World-Analyse;Senologie - Zeitschrift für Mammadiagnostik und -therapie;2024-03

2. The Endocrine Treatment Landscape for Patients with HR+ HER2− Early-stage Breast Cancer in Germany Before the Introduction of CDK4/6 Inhibitor Therapy – A Real-World Analysis;Geburtshilfe und Frauenheilkunde;2023-07-18

3. Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials;Journal of Clinical Oncology;2023-03-01

4. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study;Annals of Oncology;2022-06

5. Role of pre-metastatic niche in organ specificity of breast cancer metastasis. Influence on metastatic potential as a basis for CDK4/6-inhibition efficacy in early therapy of disseminated hormone-receptor-positive disease;Meditsinskiy sovet = Medical Council;2021-12-08